Solid Tumor Oncology Education Foundation Sponsors Free Local Seminars

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

SECAUCUS, NJ--To accommodate community-based physicians who may not be able to attend national professional meetings, the newly formed not-for-profit Solid Tumor Oncology Education Foundation, Inc. will sponsor a series of free local seminars and audioconferences, led by a faculty of expert physicians.

SECAUCUS, NJ--To accommodate community-based physicians who maynot be able to attend national professional meetings, the newlyformed not-for-profit Solid Tumor Oncology Education Foundation,Inc. will sponsor a series of free local seminars and audioconferences,led by a faculty of expert physicians.

The programs will focus on breast, colorectal, gastrointestinal,genitourinary, gynecologic, pancreatic, and lung cancers, andinclude such subjects as adjuvant and palliative therapy, currentand new protocol regimens, screening and diagnosis, and quality-of-lifeissues.

Beginning this month, the Foundation will offer a series of presentationsconducted at local, state, and regional oncology meetings by leadingoncolo-gists, as well as telephone audioconfer-ences, allowinghealth-care professionals to participate from their home or office.

The chairman of the Foundation is Paul A. Bunn, Jr., MD, Universityof Colorado Cancer Center. Board members are Laurence H. Baker,DO, University of Michigan Comprehensive Cancer Center; GabrielN. Hortobágyi, MD, University of Texas M.D. Anderson CancerCenter; John S. Macdonald, MD, Temple University Cancer Center;Robert F. Ozols, MD, PhD, Fox Chase Cancer Center, and ElizabethJ. Shpall, MD, University of Colorado Health Sciences Center.

The formation of the Foundation was made possible by an unrestrictededucational grant from Lilly Oncology. Oncolo-gists can get moreinformation by calling 1-800-223-8978.

Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Related Content